Targeting the Androgen Receptor in Breast Cancer

Current Oncology Reports

Volumn 17, Issue 2, 2015, Pages

  Chia, KeeMing ^a   O’Brien, Megan ^a   Brown, Myles ^d,e   Lim, Elgene ^a,b,c,d,e  

^a OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c LA TROBE UNIVERSITY   (Australia)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e HARVARD UNIVERSITY   (United States)

Author keywords

Androgen receptor; Androgen receptor directed therapy; Breast cancer; Breast cancer subtype

Indexed keywords

ANDROGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ANDROGEN RECEPTOR ANTAGONIST; ANTIANDROGEN; ANTINEOPLASTIC AGENT;

BINDING SITE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER THERAPY; CELL PROLIFERATION; CLINICAL PRACTICE; ESTROGEN RESPONSIVE ELEMENT; FEMALE; HEALTH CARE QUALITY; HUMAN; ONCOGENE C MYC; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION; BREAST NEOPLASMS; CHEMISTRY; CLINICAL TRIAL (TOPIC); MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANDROGEN ANTAGONISTS; ANDROGEN RECEPTOR ANTAGONISTS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY;

EID: 84922785949     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-014-0427-8     Document Type: Review

References (50)

1. Park S, Koo JS, Kim MS, Park HS, Lee JS, Lee JS, et al. Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. Ann Oncol: Off J Eur Soc Med Oncol / ESMO. 2011;22(8):1755–62.
2. Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM, Bhargava R. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol: Off J U S Can Acad Pathol Inc. 2010;23(2):205–12.
3. Qi JP, Yang YL, Zhu H, Wang J, Jia Y, Liu N, et al. Expression of the androgen receptor and its correlation with molecular subtypes in 980 chinese breast cancer patients. Breast Cancer: Basic Clin Research. 2012;6:1–8.
4. Ni M, Chen Y, Lim E, Wimberly H, Bailey ST, Imai Y, et al. Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell. 2011;20(1):119–31. Describes the enrichment of AR in ER-?HER2+ breast cancers and provides a mechanism by which AR signalling can activate HER2 signalling via Wnt and HER3. Impairment of AR-induced cell proliferation by either AR, Wnt or HER2 blockage has clinical implications.
5. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–67. Identifies six subtypes within the triple negative breast cancers including the AR(+) luminal androgen subtype characterized by a steriod hormone gene signature, which confers sensitivity to bicalutamide, and a high frequency of PIKCA mutations.
6. Safarpour D, Pakneshan S, Tavassoli FA. Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified? Am J Cancer Res. 2014;4(4):353–68.
7. Micello D, Marando A, Sahnane N, Riva C, Capella C, Sessa F. Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers. Virchows Archiv: Int J Pathol. 2010;457(4):467–76.
8. Council on Drugs, Subcommittee on Breast and Genital Cancer, Committee on Research. A.M.A. Androgens and estrogens in the treatment of disseminated mammary carcinoma - Retrospective study of 944 patients. JAMA. 1960;172:1271–83.
9. Jordan VC, Robinson SP. Species-specific pharmacology of antiestrogens: role of metabolism. Fed Proc. 1987;46(5):1870–4.
10. Goldenberg IS. Testosterone propionate therapy in breast cancer. JAMA. 1964;188:1069–72.
11. Boni C, Pagano M, Panebianco M, Bologna A, Sierra NM, Gnoni R, et al. Therapeutic activity of testoterone in metastatic breast cancer. Anticancer Res. 2014;34(3):1287–90.
12. Ingle JN, Twito DI, Schaid DJ, Cullinan SA, Krook JE, Mailliard JA, et al. Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis. Cancer. 1991;67(4):886–91.
13. Gordan GS, Halden A, Horn Y, Fuery JJ, Parsons RJ, Walter RM. Calusterone (7beta,17alpha-dimethyltestosterone) as primary and secondary therapy of advanced breast cancer. Oncology. 1973;28(2):138–46.
14. Dobs AS, Boccia RV, Croot CC, Gabrail NY, Dalton JT, Hancock ML, et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol. 2013;14(4):335–45.
15. Perrault DJ, Logan DM, Stewart DJ, Bramwell VH, Paterson AH, Eisenhauer EA. Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study. Investig New Drugs. 1988;6(3):207–10.
16. Millward MJ, Cantwell BM, Dowsett M, Carmichael J, Harris AL. Phase II clinical and endocrine study of Anandron (RU-23908) in advanced post-menopausal breast cancer. Br J Cancer. 1991;63(5):763–4.
17. Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res: Off J Am Assoc Cancer R. 2013;19(19):5505–12. The first clinical trial to demonstrate therapeutic efficacy of AR-targeted therapy in ER-/AR + breast cancers.
18. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (New York, NY). 2009;324(5928):787–90.
19. Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012;72(6):1494–503.
20. Wong YN, Ferraldeschi R, Attard G, de Bono J. Evolution of androgen receptor targeted therapy for advanced prostate cancer. Nat Rev Clin Oncol. 2014;11(6):365–76.
21. Peters AA, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM, et al. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res. 2009;69(15):6131–40.
22. Lanzino M, De Amicis F, McPhaul MJ, Marsico S, Panno ML, Ando S. Endogenous coactivator ARA70 interacts with estrogen receptor alpha (ERalpha) and modulates the functional ERalpha/androgen receptor interplay in MCF-7 cells. J Biol Chem. 2005;280(21):20421–30.
23. Hu R, Dawood S, Holmes MD, Collins LC, Schnitt SJ, Cole K, et al. Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res: Off J Am Assoc Cancer Res. 2011;17(7):1867–74.
24. Castellano I, Allia E, Accortanzo V, Vandone AM, Chiusa L, Arisio R, et al. Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res Treat. 2010;124(3):607–17.
25. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, Carey M, Agarwal R, Meric-Berstam F, et al. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2009;15(7):2472–8.
26. De Amicis F, Thirugnansampanthan J, Cui Y, Selever J, Beyer A, Parra I, et al. Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010;121(1):1–11.
27. Cops EJ, Bianco-Miotto T, Moore NL, Clarke CL, Birrell SN, Butler LM, et al. Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors. J Steroid Biochem Mol Biol. 2008;110(3–5):236–43.
28. Rizza P, Barone I, Zito D, Giordano F, Lanzino M, De Amicis F, et al. Estrogen receptor beta as a novel target of androgen receptor action in breast cancer cell lines. Breast Cancer Res: BCR. 2014;16(1):R21.
29. Vera-Badillo FE, Templeton AJ, de Gouveia P, Diaz-Padilla I, Bedard PL, Al-Mubarak M, et al. Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(1):djt319.
30. Park S, Park HS, Koo JS, Yang WI, Kim SI, Park BW. Higher expression of androgen receptor is a significant predictor for better endocrine-responsiveness in estrogen receptor-positive breast cancers. Breast Cancer Res Treat. 2012;133(1):311–20.
31. Nakopoulou L, Lazaris AC, Panayotopoulou EG, Giannopoulou I, Givalos N, Markaki S, et al. The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer. J Clin Pathol. 2004;57(5):523–8.
32. Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA. Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci U S A. 2004;101(6):1566–71.
33. Omoto Y, Eguchi H, Yamamoto-Yamaguchi Y, Hayashi S. Estrogen receptor (ER) beta1 and ERbetacx/beta2 inhibit ERalpha function differently in breast cancer cell line MCF7. Oncogene. 2003;22(32):5011–20.
34. Grober OM, Mutarelli M, Giurato G, Ravo M, Cicatiello L, De Filippo MR, et al. Global analysis of estrogen receptor beta binding to breast cancer cell genome reveals an extensive interplay with estrogen receptor alpha for target gene regulation. BMC Genomics. 2011;12:36.
35. Macedo LF, Guo Z, Tilghman SL, Sabnis GJ, Qiu Y, Brodie A. Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Res. 2006;66(15):7775–82.
36. Chanplakorn N, Chanplakorn P, Suzuki T, Ono K, Wang L, Chan MS, et al. Increased 5alpha-reductase type 2 expression in human breast carcinoma following aromatase inhibitor therapy: the correlation with decreased tumor cell proliferation. Horm Cancer. 2011;2(1):73–81.
37. Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D’Amato NC, et al. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res: BCR. 2014;16(1):R7. Indentifies an association between high nuclear AR-ER ration and tamoxifen failure and demonstrates the efficacy of enzalutamide in abolishing DHT-induced proliferation of ER-/AR + breast cancer cells and estradiol-induced proliferation of ER+/AR + breast cancer cells.
38. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 2008;68(3):826–33.
39. Loh YN, Hedditch EL, Baker LA, Jary E, Ward RL, Ford CE. The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer. BMC Cancer. 2013;13:174.
40. Huang R, Faratian D, Sims AH, Wilson D, Thomas JS, Harrison DJ, et al. Increased STAT1 signaling in endocrine-resistant breast cancer. PLoS One. 2014;9(4):e94226.
41. Morrison G, Fu X, Shea M, Nanda S, Giuliano M, Wang T, et al. Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance. Breast Cancer Res Treat. 2014;144(2):263–72.
42. Tilghman SL, Townley I, Zhong Q, Carriere PP, Zou J, Llopis SD, et al. Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness. Mol Cell Proteomics: MCP. 2013;12(9):2440–55.
43. Vilquin P, Villedieu M, Grisard E, Ben Larbi S, Ghayad SE, Heudel PE, et al. Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor. Int J Cancer J Int du Cancer. 2013;133(7):1589–602.
44. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene. 2005;24(29):4660–71.
45. Robinson JL, Macarthur S, Ross-Innes CS, Tilley WD, Neal DE, Mills IG, et al. Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J. 2011;30(15):3019–27.
46. Chia KM, Liu J, Francis GD, Naderi A. A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer. Neoplasia (New York, NY). 2011;13(2):154–66.
47. Ni M, Chen Y, Fei T, Li D, Lim E, Liu XS, et al. Amplitude modulation of androgen signaling by c-MYC. Genes Dev. 2013;27(7):734–48.
48. Naderi A, Chia KM, Liu J. Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer. Breast Cancer Res: BCR. 2011;13(2):R36.
49. Lehmann BD, Bauer JA, Schafer JM, Pendleton CS, Tang L, Johnson KC, et al. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res: BCR. 2014;16(4):406. The authors have identified a high prevalence of P13KCA mutations in AR + TNBC and have demonstrated an additive effect from combined anti-AR and P13K inhibition which provides a pre-clinical rationale for future investigation using this combination in a clinical setting.
50. Cuenca-Lopez MD, Montero JC, Morales JC, Prat A, Pandiella A, Ocana A. Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling. BMC Cancer. 2014;14:302.